View document text
Date: November 13, 2026
National Stock Exchange of India Limited, BSE Limited,
Exchange Plaza, C-1, Block G, 20th Floor, P.J. Towers,
Bandra Kurla Complex, Bandra (E), Dalal Street,
Mumbai – 400 051 Mumbai - 400001.
NSE Scrip Symbol: MANIPALHOS BSE Scrip Code: 544847
Subject: Press Release and Investor Presentation for the Earnings Conference Call with Analysts and
Investors of Manipal Health Enterprises Limited (the “Company”)
Dear Sir/Ma’am,
Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (“SEBI Listing Regulations”), please find enclosed the Press Release and
Investor Presentation in connection with the earnings conference call scheduled to be held today i.e.,
November 13, 2026, to discuss the Unaudited (Standalone and Consolidated) Financial Results of the
Company for the quarter and half year ended September 30, 2026.
The above announcements will also be uploaded on the website of the Company and can be accessed using
the link: https://www.manipalhospitals.com/mhel-financial-reports#investor-earnings-call
This intimation is being submitted for your information and records.
Thank you.
For Manipal Health Enterprises Limited
(formerly Manipal Health Enterprises Private Limited)
Sathish K R
Company Secretary and Compliance Officer
Membership No.: A15203
MHE-Public
Manipal Hospitals Delivers 37.3% Revenue Growth in Q2 FY27, EBITDA Rises 29.8%.
Patient-led growth momentum support performance across the network
Bengaluru, Karnataka, November 13, 2026: Manipal Health Enterprises Limited (Manipal Hospitals),
India’s largest pan-India multi-specialty hospital networks by bed capacity, today announced its
financial results for the quarter ended September 30, 2026 (Q2 FY27).
The company delivered a strong operating performance during the quarter, supported by sustained
patient demand, growth in high-acuity specialties and capacity absorption. Improving occupancy and
operating efficiencies further strengthened the performance of the expanded network.
Operating Performance
Revenue from operations stood at ₹ 3,399 crore in Q2 FY27, registering 37.3% year-on-year growth,
while EBITDA stood at ₹ 882 crore, up 29.8% year-on-year. EBITDA margin was 26.0%, and 26.8%
excluding Sahyadri. For H1 FY27, revenue reached ₹ 6,490 crore, up 37.7%, and EBITDA reached ₹
1,631 crore, up 28.2%. Excluding the ₹ 15 crore one-off gain in H1 FY26, EBITDA growth was 29.8%.
Sahyadri, acquired on October 3, 2025, is included in the current-period consolidated results but not
in the corresponding prior-year periods.
Inpatient volumes grew 35.0% to approximately 169,000 and outpatient volumes rose 27.2% to
approximately 1.74 million during Q2 FY27. Occupancy improved by 160 basis points year-on-year to
70.1%, with average operational capacity of 7,331 beds and average length of stay of 2.8 days. The
300-licensed-bed Electronic City hospital in Bengaluru opened during the quarter, taking the
network’s licensed bed capacity to 13,440 as of September 30, 2026.
Reported PAT stood at ₹ 285 crore in Q2 FY27. PAT excluding exceptional items was ₹ 380 crore, up
21.6% year-on-year; additionally excluding ₹ 75 crore of post-tax interest on the NCD raised for the
Sahyadri acquisition, PAT was ₹ 455 crore, up 45.6%. Consolidated ARPOB stood at ₹ 70,600 per day;
excluding Sahyadri, ARPOB was ₹ 76,600 per day, up 8.5%. Net debt, excluding lease liabilities, stood
at ₹ 343 crore at quarter-end, with net debt to annualised EBITDA of 0.10 times.
Sahyadri Integration Supports Growth
Sahyadri Hospitals contributed ₹ 375 crore in revenue and ₹ 73 crore in EBITDA during Q2 FY27. For
H1 FY27, revenue reached ₹ 707 crore, up 17.8%*, and EBITDA reached ₹ 131 crore, up 24.1%*. H1
occupancy was 67.0%, up 270 basis points, while ARPOB increased 12.5% to ₹ 44,100 per day.
Integration progressed through the rollout of centralised procurement rates and the addition and
enhancement of clinical capability & programs. Digital revenue contribution at Sahyadri reached 11%,
supported by continued digital engagement and community outreach initiatives. The phased brand
transition has been initiated with a Q4 FY27 timeline, while the nine-hospital Pune cluster is being
developed as an integrated network with shared leadership, referrals and clinical capabilities.
High-Acuity Specialties Continue to Drive Momentum
The six CONGO-R Centres of Excellence—Cardiac Sciences, Oncology, Neurosciences,
Gastroenterology, Orthopedics and Renal Sciences—continued to support high-acuity care across the
network. In H1 FY27, oncology revenue grew 51% year-on-year, neurosciences 47% and orthopedics
Manipal Health Enterprises Limited
98, HAL Old Airport Rd, Kodihalli
Bengaluru, Karnataka 560017, India
44%, with cardiac sciences, gastroenterology and renal sciences growing 39%, 36% and 38%,
respectively. These consolidated growth rates reflect the expanded network as well as operating
performance. Investments during the half year included advanced oncology equipment at Nashik, an
AI-assisted neuro biplane cath lab at Mukundpur, orthopedic robots at Patiala, Vijayawada and Pune
Baner, and an AI-enabled cath lab at Old Airport Road.
Performance Highlights:
Particulars (₹ Cr) Q2 FY27 Q2 FY26 YoY Q1 FY27 QoQ H1 FY27 H1 FY26 YoY
Revenue from
3,399.4 2,475.4 37.3% 3,090.6 10.0% 6,490.0 4,713.1 37.7%
Operations
EBITDA 882.2 679.8 29.8% 749.0 17.8% 1,631.2 1,272.4 28.2%
EBITDA Margin % 26.0% 27.5% -150 bps 24.2% 180 bps 25.1% 27.0% -190 bps
PAT (excluding
380.2 312.7 21.6% 258.9 46.7% 639.1 585.1 9.2%
Exceptions)
PAT Margin %
11.2% 12.6% -140 bps 8.4% 280 bps 9.8% 12.4% -260 bps
(Ex-Exceptions)
ARPOB (₹/day) 70,600 70,600 0.0% 71,500 -1.3% 71,100 70,800 0.4%
Occupancy % 70.1% 68.5% 160 bps 65.0% 510 bps 67.6% 65.3% 230 bps
Notes: EBITDA excludes other income and ESOP expenses. H1 FY26 EBITDA includes a one-off gain of ₹ 15 crore; excluding this, H1 FY27
EBITDA growth was 29.8%. PAT and PAT margin in the table are reported figures excluding exceptional items. PAT including exceptional
items was ₹ 285.0 crore in Q2 FY27, ₹ 317.8 crore in Q2 FY26, ₹ 243.4 crore in Q1 FY27, ₹ 528.4 crore in H1 FY27 and ₹ 571.8 crore in H1
FY26. Additionally excluding post-tax Sahyadri acquisition NCD interest of ₹ 75 crore in Q2 FY27 and ₹ 165 crore in H1 FY27, PAT was
approximately ₹ 455 crore and ₹ 804 crore, respectively, up 45.6% and 37.4% year-on-year. ARPOB in the table is consolidated and rounded
to the nearest ₹ 100; excluding Sahyadri, Q2 and H1 FY27 ARPOB was ₹ 76,600 and ₹ 76,900 per day, up 8.5% and 8.6%, respectively. Changes
in margins and occupancy are expressed in basis points using the displayed rounded percentages; Current-period consolidated results
include Sahyadri; corresponding prior-year consolidated periods do not.
Commenting on the Q2 FY27 performance, Dilip Jose, Managing Director & CEO, Manipal Hospitals,
said:
“We are pleased that our performance this quarter has been driven by volumes with more patients
accessing our care and this we believe is the sustainable option for growth in care delivery. Improved
capacity utilisation, particularly in high-acuity specialties continued to be a key driver while
maintaining focus on strengthening our clinical capabilities, improving operational performance and
building a more integrated healthcare platform.”
About Manipal Hospitals:
Manipal Hospitals is one of India’s leading integrated healthcare providers serving ~ 8 million patients
annually, focussed on providing accessible, high-quality healthcare services. Manipal’s integrated
network today has a Pan-India footprint of 50 hospitals with over 13,400 licensed beds across 14
States & Union Territories. The network is India’s largest multispecialty hospital network by bed
capacity, supported by a talented pool of 11,000+ doctors and an employee strength of over 25,000.
With a commitment to provide patient-centric care, Manipal Hospitals combines clinical experti
[Showing first 8,000 characters — download PDF for full document]